Jones Financial Companies
OVID icon

Jones Financial Companies’s Ovid Therapeutics OVID Stock Holding History

Jones Financial Companies’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.46K Hold
2,925
– – ﹤0.01% 3907
2026
Q1 		$6.73K Buy
+2,925
New +$5.23K ﹤0.01% 3726

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jones Financial Companies's OVID Position: Q2 2026 in Review

Jones Financial Companies held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 2,925 shares worth $7.46K. The position accounts for ﹤0.01% of the portfolio, ranked #3907.

Jones Financial Companies first reported a position in OVID in Q1 2026 and has held it in 2 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Jones Financial Companies held 2,925 shares of Ovid Therapeutics worth $7.46K as of Q2 2026.
  • Jones Financial Companies left its Ovid Therapeutics share count unchanged in Q2 2026.
  • Ovid Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #3907 holding.
  • Jones Financial Companies first reported a position in Ovid Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.